Incretin & Metabolic Receptor Agonists
Semaglutide
Also known as Ozempic · Wegovy · Rybelsus
Last reviewed: 2026-11-19
Overview
Regulatory status
FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.
Ozempic · Type 2 Diabetes
Glycemic control in adults with type 2 diabetes, with diet and physical activity.
Authoritative label recordWegovy · Weight Management
Long-term weight reduction in adults with obesity, or overweight with a weight-related condition; the indicated product also covers patients 12 and older with obesity.
Authoritative label recordWegovy · Cardiovascular Risk
Major cardiovascular event risk reduction in adults with established cardiovascular disease and overweight or obesity.
Authoritative label recordWegovy injection · Liver Disease
Treatment of noncirrhotic MASH with moderate-to-advanced liver fibrosis (F2–F3) in adults; accelerated approval based on a surrogate endpoint, with confirmation of clinical benefit required.
Authoritative label record
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextEvidence at a glance
Large randomized trials support product-specific indications; results depend on the population, endpoints and approved formulation.
Key sources
Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.
Related compounds
- Retatrutide
Same scientific class · A 39-amino-acid chain. · Late-stage human trials
- Tirzepatide
Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications